Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Medtronic
McKinsey
AstraZeneca
Mallinckrodt
Cerilliant
Julphar
Chinese Patent Office
Accenture

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,569,610

« Back to Dashboard

Which drugs does patent 7,569,610 protect, and when does it expire?

Patent 7,569,610 protects APLENZIN and is included in one NDA.

This patent has forty-nine patent family members in seventeen countries.
Summary for Patent: 7,569,610
Title:Modified release formulations of a bupropion salt
Abstract:The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s): Oberegger; Werner (Mississauga, CA), Maes; Paul (Toronto, CA), Saleh; Mohammad Ashty (Oakville, CA)
Assignee: Biovail Laboratories International SRL (St. Michael, BB)
Application Number:11/751,768
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,569,610

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS ➤ Sign Up
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS ➤ Sign Up
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,569,610

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,354,453 Bupropion hydrobromide and therapeutic applications ➤ Sign Up
7,241,805 Modified release formulations of a bupropion salt ➤ Sign Up
7,569,611 Modified release formulations of a bupropion salt ➤ Sign Up
7,645,901 Modified release formulations of a bupropion salt ➤ Sign Up
7,884,136 Modified-release formulations of a bupropion salt ➤ Sign Up
7,572,935 Modified release formulations of a bupropion salt ➤ Sign Up
7,585,897 Modified release formulations of a bupropion salt ➤ Sign Up
7,649,019 Modified release formulations of a bupropion salt ➤ Sign Up
7,645,802 Bupropion hydrobromide and therapeutic applications ➤ Sign Up
7,579,380 Modified release formulations of a bupropion salt ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,569,610

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006261788 ➤ Sign Up
Australia 2008285660 ➤ Sign Up
Australia 2008320915 ➤ Sign Up
Canada 2578626 ➤ Sign Up
Canada 2655596 ➤ Sign Up
Canada 2699588 ➤ Sign Up
Canada 2700733 ➤ Sign Up
China 101534808 ➤ Sign Up
China 101784266 ➤ Sign Up
China 101903016 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Citi
Boehringer Ingelheim
Teva
QuintilesIMS
Accenture
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot